Two pharmaceutical companies make IVIG. Company A produces their product from pools of 100,000 donors drawn exclusively from the population of the United States. Company B makes their IVIG from pools of 60,000 donors drawn in equal numbers from North America, Europe, Brazil, and Japan.a. Which product would you expect to have the broadest spectrum of pathogen reactivities? Why?b. Assume the patients receiving the antibody will (1) never leave the USA, or (2) travel extensively in many parts of the world. Which companys product would you choose for each of these patient groups? Justify your choices.1. Indicate whether each of the following statements is true or false. If you think a statement is false, explain why.a. A rabbit immunized with human IgG3 will produce anti- body that reacts with all subclasses of IgG in humans.b. All immunoglobulin molecules on the surface of a given B cell have the same idiotype.c. All immunoglobulin molecules on the surface of a given B cell have the same isotype.d. All myeloma protein molecules derived from a single myeloma clone have the same idiotype and allotype.e. Although IgA is the major antibody species that under- goes transcytosis, polymeric IgM, but not monomeric IgA, can also undergo transcytosis.f. The hypervariable regions make significant contact with the epitope.g. IgG functions more effectively than IgM in bacterial ag- glutination.h. Although monoclonal antibodies are often preferred for research and diagnostic purposes, both monoclonal and polyclonal antibodies can be highly specific.i. All isotypes are normally found in each individual of a species.j. The heavy-chain variable region (VH) is twice as long as the light-chain variable region (VL).